Press Releases
Date Title and Summary View
Aug 4, 2016 Second quarter revenues increased 38 percent year-over-year Sparsentan top-line data expected in third quarter of 2016 RE-024 efficacy trial expected to initiate in second half of 2016 SAN DIEGO, Aug. 04, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today reported its second quarter 2016 financial results. Net product sales for...
Jul 21, 2016 SAN DIEGO, July 21, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced it will report second quarter 2016 financial results on Thursday, August 4, 2016 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:3...
Jul 19, 2016 SAN DIEGO, July 19, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced the appointment of Roy D. Baynes, M.D., Ph.D., to its Board of Directors, effective immediately. Dr. Baynes currently serves as senior vice president of Global Clinical Development at Merck Research Laboratories. "I am pleased to welcome Dr. Baynes to ...
Jun 23, 2016 SAN DIEGO, June 23, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced new data from physician-initiated treatment with RE-024, the company's novel investigational replacement therapy for pantothenate kinase-associated neurodegeneration (PKAN), a rare and life-threatening genetic condition characterized by a host of progressiv...
Jun 20, 2016 SAN DIEGO, June 20, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced the signing of a definitive agreement to purchase the rights, titles, and ownership of a liquid formulation of ursodeoxycholic acid from Asklepion Pharmaceuticals, LLC. Retrophin intends to file a New Drug Application with the U.S. Food and Drug Administrat...
May 26, 2016 SAN DIEGO, May 26, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage, chief executive officer, will present at the following upcoming investor conferences: Jefferies 2016 Healthcare Conference in New York City on Thursday, June 9, 2016 at 2:30 p.m. ET JMP Securities Life Sciences Conference in New Yo...
May 3, 2016 First quarter revenues increased 67 percent year-over-year Enrollment of the Phase 2 DUET study of sparsentan completed; top-line results expected third quarter 2016 SAN DIEGO, May 03, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today reported its first quarter 2016 financial results. Net product sales for the first quarter 2016...
Apr 21, 2016 SAN DIEGO, April 21, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage, chief executive officer, will present at the Deutsche Bank 41st Annual Health Care Conference in Boston on Thursday, May 5, 2016 at 2:10 p.m. ET.   A live webcast of the presentation will be available at http://ir.retrophin.com/e...
Apr 19, 2016 SAN DIEGO, April 19, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced it will report first quarter 2016 financial results on Tuesday, May 3, 2016 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p....
Apr 4, 2016 SAN DIEGO, April 04, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced Gary A. Lyons will become the Company's next independent Chairman of the Board of Directors, effective at the conclusion of the annual meeting of stockholders, to be held on May 18, 2016. Mr. Lyons, an independent director of Retrophin since 2014, will suc...
Page: FirstPrevious
3
... NextLast
= add release to Briefcase